Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:10/30/2008

CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2008. At September 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $60.1 million.

2008 Year-to-Date Business Highlights

-- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log10 after seven days of treatment in each of the 800 mg, 400 mg, 200 mg and 100 mg dosing cohorts (n=8 per treatment group). Patients receiving placebo (n=8) had a mean viral load increase of 0.10 log10 over the same treatment period. The safety profile of IDX899 observed during this study was comparable to placebo, with no serious adverse events reported and no pattern of adverse events or laboratory abnormalities observed on treatment. Additionally, no patients who received treatment discontinued the study.

-- Idenix also continued to advance its HCV discovery and development programs, successfully completing a first-in-man phase I study of IDX184, a nucleotide prodrug candidate, and initiating the IND-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and IDX136 and IDX316, macrocyclic protease inhibitor drug candidates.

"As we advance our HCV and HIV discovery and devel
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the leading ... products to hospitals, physician office laboratories and alternate ... October 1, 2014, it will serve as Siemens ... market segments and as a semi-exclusive sales distributor ... contiguous United States . LABSCO ...
(Date:9/16/2014)... 2014 BCC Research reveals in ... CELLS , the global market for stem cells is ... with a five-year compound annual growth rate (CAGR) of ... Americas with growth projections of $2.2 billion in 2014 ... http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications of ...
(Date:9/15/2014)... 15, 2014   Global Science & Technology, ... products and services for satellite and weather systems, ... Integrated Services (OASIS) from the General Services Administration ... to provide the government best-value solutions for complex ... category in Pool 4. The OASIS SB award ...
(Date:9/15/2014)... from North Carolina State University have developed a technique ... applying very low voltages, opening the door to a ... technologies. The technique hinges on the fact that the ... deposited or removed acts as a surfactant, lowering ... fluid. , The researchers used a liquid metal alloy ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Researchers control surface tension to manipulate liquid metals 2
... Jan. 19, 2012  SynCardia Systems, Inc. ( www.syncardia.com ... Heart, announced today that on Dec. 29, 2011, ... Total Artificial Heart patient, 61-year-old Nikola Gaspic, to ... using the Freedom® portable driver . ...
... -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... that specializes in patented biopharmaceutical medicine, modernized ... active pharmaceutical ingredients (API) announced the Company ... certification for its 250-ton Jiangchuan Macrolide Facility ...
...  Synthetic Genomics Inc. (SGI), a privately held company commercializing ... of global challenges, today announced they have hired George ... is a proven leader with experience in developing sophisticated ... and nutritional products for humans and animals. At SGI ...
Cached Biology Technology:Slovenia's 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the FreedomĀ® Portable Driver 2Slovenia's 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the FreedomĀ® Portable Driver 3TPI Receives GMP Certification for JCM Facility 2TPI Receives GMP Certification for JCM Facility 3Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2
(Date:9/16/2014)... The risk of severe maternal morbidity amongst women ... suggests a new study published today (17 September) ... and Gynaecology . , Australians generally enjoy high ... that health disparities exist, in particular between indigenous ... aimed to explore the independent impact of socioeconomic ...
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... Pit Fire began on September 13, 2014. The fire ... is currently over 2,300 acres in size and is mostly ... Pit Fire was calm Monday night due to higher humidity. ... anchor point and beginning to construct a fireline on the ... resources are working on the fire: , 7 20-person Crews, ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... Obese women are as much as 28 percent ... pregnancy, according to research that earned a Michigan State ... Barbara Luke, a researcher in the MSU College of ... focused on data of nearly 50,000 women using assisted ...
... the UCLA Henry Samueli School of Engineering and Applied ... the laboratory the enzyme responsible for producing the blockbuster ... published Oct. 23 in the journal Science , ... with similarly beneficial effects. The ...
... at Chicago have received $1 million from the National ... between "fat taxes" and food consumption, diet quality and ... made available through the American Recovery and Reinvestment Act ... rates associated with restaurants and with specific sugar- and ...
Cached Biology News:MSU researcher: Obesity significantly cuts odds of successful pregnancy 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2UIC receives $1 million grant to study 'fat taxes,' diet, obesity 2
... SDSaway reagent is a valuable tool for ... The presence of SDS in biological samples ... bound SDS-protein complex, inhibits enzymatic activity during ... as a contaminant in mass spectrometry analyses. ...
... cGMP Safe Deposit Service ECACC is able ... requirements of cGMP for cryo-storage. The cell lines ... they have been produced in accordance with the ... tested for freedom from mycoplasma, bacteria or fungi. ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... has 20 years of expertise in the ... still offers the most powerful systems on ... to 40 000 in-microplate tests requiring incubation ... of different modules (such as worktable shaker ...
Biology Products: